A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression
A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression
Sponsor: Ambrx, Inc.
Terminated
Replace with a new trial
A PHASE1 clinical study on Breast Neoplasms and Stomach Neoplasms, this trial is terminated or withdrawn. The trial is conducted by Ambrx, Inc. and has accumulated 8 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jul 2020 — Jan 2021 [monthly]
Terminated PHASE1
Status: Unknown Status → Terminated
-
Jul 2019 — Jul 2020 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Jul 2019 [monthly]
Recruiting PHASE1
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Jul 2017 [monthly]
Recruiting PHASE1
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ambrx, Inc.
- Zhejiang Medicine Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .